XR:NTX vs XR:B (Brixadi) (034)


Study Information

The Friends Research Institute JCOIN Research Center is conducting a comparative effectiveness trial of extended-release naltrexone (XR-NTX) versus a new extended-release formulation of buprenorphine (Brixadi, XR-B) to treat opioid use disorder (OUD) among justice-involved individuals in ten Maryland county jails.

Participants will be randomly assigned to receive either XR-NTX or XR-B prior to release from jail, followed by six monthly injections while in the community. The goal of the study is to evaluate the effectiveness of the two medications, measure medication adherence, and gather data to inform broader scale-up of medications for opioid use disorder (MOUD) in jails and in the community.

Study Settings: Jails/Prisons, Treatment/Healthcare Settings

Study Location: Maryland

Grant number: UG1DA050077

Link to NIH Reporter record:  https://reporter.nih.gov/project-details/9882422

Study Team

PI: Shannon Mitchell, Michael Gordon, DPA

Logo of Friends Research Institute (FRI)

Study Aims

• Determine the effectiveness of XR-B versus XR-NTX

• Identify factors related to acceptability/feasibility of providing MOUD in jails

• Measure outcomes including substance use, overdose, and recidivism

• Identify best practices to inform expanded use of extended-release MOUD in jails and in the community

• Calculate the cost of implementing these medications in justice settings

Research Type

Clinical Trial, MOUD Comparative Effectiveness